HIV cure trial mergers: Spotlighting the epigenetics of latency reversal

Affiliations

Comment

Paul W Denton. EBioMedicine. 2022 May.

. 2022 May:79:104012.

doi: 10.1016/j.ebiom.2022.104012. Epub 2022 Apr 19.

¹ Department of Biology, University of Nebraska Omaha, Omaha, NE, USA. Electronic address: pdenton@unomaha.edu.

No abstract available

Conflict of interest statement

Declaration of interests The author declares no conflicts of interest.

Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.
Oriol-Tordera B, Esteve-Codina A, Berdasco M, Rosás-Umbert M, Gonçalves E, Duran-Castells C, Català-Moll F, Llano A, Cedeño S, Puertas MC, Tolstrup M, Søgaard OS, Clotet B, Martínez-Picado J, Hanke T, Combadiere B, Paredes R, Hartigan-O'Connor D, Esteller M, Meulbroek M, Calle ML, Sanchez-Pla A, Moltó J, Mothe B, Brander C, Ruiz-Riol M. Oriol-Tordera B, et al. EBioMedicine. 2022 Apr;78:103956. doi: 10.1016/j.ebiom.2022.103956. Epub 2022 Mar 21. EBioMedicine. 2022. PMID: 35325780 Free PMC article.

1. Dybul M., Attoye T., Baptiste S., et al. The case for an HIV cure and how to get there. Lancet HIV. 2021;8(1):e51–e58. doi: 10.1016/s2352-3018(20)30232-0. - DOI - PMC - PubMed
1. Deeks S.G., Archin N., Cannon P., et al. Research priorities for an HIV cure: international AIDS society global scientific strategy 2021. Nat Med. 2021;27(12):2085–2098. doi: 10.1038/s41591-021-01590-5. - DOI - PubMed
1. Margolis D.M., Archin N.M., Cohen M.S., et al. Curing HIV: seeking to target and clear persistent infection. Cell. 2020;181(1):189–206. doi: 10.1016/j.cell.2020.03.005. - DOI - PMC - PubMed
1. Sneller M.C., Justement J.S., Gittens K.R., et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med. 2017;9(419) doi: 10.1126/scitranslmed.aan8848. - DOI - PMC - PubMed
1. Oriol-Tordera B., Esteve-Codina A., Berdasco M., et al. Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. EBioMedicine. 2022;78(103956) doi: 10.1016/j.ebiom.2022.103956. - DOI - PMC - PubMed